2025. Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe ​ Atopic Dermatitis: Results Up to 3 Years From ADjoin. SKIN The Journal of Cutaneous Medicine. 9, 1 (Jan. 2025), s510. DOI:https://doi.org/10.25251/skin.9.supp.510.